CD274 and neoplasm: The authors concluded that this 4-year update demonstrateed that patients treated with nivolumab plus ipilimumab with chemotherapy continue to experience a long-term, durable efficacy benefit over chemotherapy alone, irrespective of tumor PD-L1 expression and histology.